Skip to main content

Invasive fungal infections (IFIs) continue to pose a significant toll on human health, especially for immunocompromised individuals.

IFIs – a global public health problem

It is estimated that more than 150 million people worldwide suffer from a serious fungal disease. For example, recent global estimates found 3,000,000 cases of chronic pulmonary aspergillosis, ~700,000 cases of invasive candidiasis, ~250,000 cases of invasive aspergillosis, ~500,000 cases of Pneumocystis jirovecii pneumonia, ~100,000 cases of disseminated histoplasmosis, and over 10,000,000 cases of fungal asthma occur annually.(1)
The incidence of IFIs is rising largely because of the number of immunocompromised patients, including those with neutropenia, HIV, chronic immunosuppression, prostheses, burns, diabetes mellitus, and those taking broad-spectrum antibiotics. IFIs have a high mortality rate (> 50%); however, experts estimate that 80% of those patients might be saved with appropriate diagnostics and treatments.